Jose Carlos Solana
Overview
Explore the profile of Jose Carlos Solana including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
98
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Solana J, Bernardo L, Moreno J, Aguado B, Requena J
Genes (Basel)
. 2022 May;
13(5).
PMID: 35627127
Abrupt environmental changes are faced by parasites during transmission from a poikilothermic insect vector to a warm-blooded host. Adaptation to harsh environmental conditions, such as nutrient deprivation, hypoxia, oxidative stress...
12.
Fernandez L, Solana J, Sanchez C, Jimenez M, Requena J, Coler R, et al.
Microorganisms
. 2021 Nov;
9(11).
PMID: 34835379
Visceral leishmaniasis (VL) is the most severe clinical form of leishmaniasis, fatal if untreated. Vaccination is the most cost-effective approach to disease control; however, to date, no vaccines against human...
13.
Soto M, Ramirez L, Solana J, Cook E, Hernandez-Garcia E, Requena J, et al.
Microorganisms
. 2021 Mar;
9(2).
PMID: 33673117
parasites are etiological agents of cutaneous leishmaniasis in the New World. BALB/c mice are highly susceptible to challenge due to their inability to mount parasite-dependent IFN-γ-mediated responses. Here, we analyzed...
14.
Bernardo L, Solana J, Romero-Kauss A, Sanchez C, Carrillo E, Moreno J
PLoS Negl Trop Dis
. 2021 Feb;
15(2):e0009126.
PMID: 33524030
The increasing use of immunosuppressants in areas where visceral leishmaniasis (VL) is endemic has increased the number of people susceptible to developing more severe forms of the disease. Few studies...
15.
Soto M, Ramirez L, Solana J, Cook E, Hernandez-Garcia E, Charro-Zanca S, et al.
Front Immunol
. 2020 Dec;
11:590934.
PMID: 33362772
Unveiling the protective immune response to visceral leishmaniasis is critical for a rational design of vaccines aimed at reducing the impact caused by this fatal, if left untreated, vector-borne disease....
16.
Solana J, Ramirez L, Cook E, Hernandez-Garcia E, Sacristan S, Martin M, et al.
Vaccines (Basel)
. 2020 Mar;
8(1).
PMID: 32210040
parasites cause a severe form of visceral leishmaniasis in human and viscerocutaneous leishmaniasis in dogs. Recently, we reported that immunization with an attenuated cell line, lacking the gene, protects against...
17.
Camacho E, Gonzalez-de la Fuente S, Rastrojo A, Peiro-Pastor R, Solana J, Tabera L, et al.
Sci Rep
. 2019 Apr;
9(1):6127.
PMID: 30992521
Leishmania donovani is a unicellular parasite that causes visceral leishmaniasis, a fatal disease in humans. In this study, a complete assembly of the genome of L. donovani is provided. Apart...
18.
Iborra S, Solana J, Requena J, Soto M
Expert Rev Vaccines
. 2018 Mar;
17(4):323-334.
PMID: 29589966
Introduction: The search for vaccines to prevent human leishmaniasis is an active field of investigation aimed to prevent the devastating effects of this family of diseases on human health. The...
19.
Solana J, Ramirez L, Corvo L, de Oliveira C, Barral-Netto M, Requena J, et al.
PLoS Negl Trop Dis
. 2017 May;
11(5):e0005644.
PMID: 28558043
Background: The immunization with genetically attenuated Leishmania cell lines has been associated to the induction of memory and effector T cell responses against Leishmania able to control subsequent challenges. A...